Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Trevena
Special Reports
The 2025 Biotech Graveyard
Biotechs, beware: You're in for a scare.
Darren Incorvaia
Oct 31, 2025 5:00am
Trevena teeters on edge with C-suite shakedown—Chutes & Ladders
Nov 8, 2024 8:30am
With 4 remaining staffers, CNS-focused Trevena nears end of road
Nov 7, 2024 10:40am
FDA pulls breakthrough status from Trevena’s pain drug
Mar 8, 2019 10:19am
FDA rejects Trevena’s painkiller oliceridine
Nov 5, 2018 7:56am
Deconstructing an opioid receptor to create safer painkillers
Jan 5, 2018 3:03pm
